AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that the Company has engaged J.S. Cole & Associates to serve as exclusive financial advisor for the Company’s partnering efforts in Japan.
J.S. Cole & Associates provides business development and marketing research services for pharmaceutical, biotechnology, medical device, and diagnostic companies. The company has worked as liaison for both licensees and licensors in the US, the Far East, and Europe, with a particular emphasis and knowledge of the Japanese healthcare industry, its landscape and its initiatives.
“In our efforts to expand business development and partnering outreach in the Far East, we are very pleased to have J.S. Cole & Associates on board with us,” said Glenn Mattes, President & CEO of TFF Pharmaceuticals. “Their long-term ties and personal contacts with some of the leading biotech and pharmaceutical companies in Japan will be a strategic advantage for us as we look to partner our technology platform in this important and growing market.”
“TFF’s technology and platform is both disruptive and a potentially strong fit with many biopharmaceutical companies in Japan,” said Steven Cole, President of J.S. Cole Associates. “We look forward to introducing the Company and its technology to potential partners, joint ventures, or other strategic alliances in this important and growing market.”
About J.S. Cole & Associates
J.S. Cole & Associates provides business development and marketing research services for pharmaceutical, biotechnology, medical device, and diagnostic companies. For over 15 years, the company has been working as liaisons for both licensees and licensors in the US, Japan, and Europe resulting in dozens of finalized deals including a significant number in Japan. For more information, please visit http://www.coleconsult.com
About TFF Pharmaceuticals’ Thin Film Freezing technology platform
TFF Pharmaceuticals’ Thin Film Freezing (TFF) platform was designed to improve the solubility and absorption of poorly water-soluble drugs and is particularly suited to generate dry powder particles with properties targeted for inhalation delivery, especially to the deep lung, an area of extreme interest in respiratory medicine. The TFF process results in a “Brittle Matrix Particle,” which possesses low bulk density, high surface area, and typically an amorphous morphology, allowing the particles to supersaturate when contacting the target site, such as lung tissue. Based upon laboratory experiments, the aerodynamic properties of the particles are such that the portion of a drug deposited to the deep lung has the potential to reach as high as 75 percent.
About TFF Pharmaceuticals
TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform. Early testing confirms that the TFF platform can significantly improve the solubility and absorption of poorly water-soluble drugs, a class of drugs that comprises approximately one-third of the major pharmaceuticals worldwide, thereby improving their pharmacokinetics. TFF Pharmaceuticals has two lead drug candidates: Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder. The Company plans to add to this pipeline by collaborating with large pharmaceutical partners. The TFF Platform is protected by 39 patents issued or pending in the US and internationally. To learn more about TFF Pharmaceuticals and its product candidates, visit the Company’s website at https://tffpharma.com.
This press release contains forward-looking statements regarding TFF Pharmaceuticals, Inc., including the development of potential business partnership in Japan through J.S. Cole & Associates, the benefits of the Company’s TFF platform and its dry powder version of Voriconazole and Tacrolimus, and the Company’s plans to add to its existing pipeline of product candidates. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) no drug product incorporating the TFF platform has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (ii) the Company has no current agreements or understandings with any large pharmaceutical companies for the development of a drug product incorporating the TFF Platform and (iii) those other risks disclosed in the section “Risk Factors” included in the Company’s Quarterly Report on Form 10-Q filed with the on December 9, 2019. TFF Pharmaceuticals cautions readers not to place undue reliance on any forward-looking statements. TFF Pharmaceuticals does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law.